Helpful Products for GLP-1 Treatment
Managing your GLP-1 medication is easier with the right tools:
-
Sharps container — Essential for safe needle disposal. A sharps container is required for home use.
-
Ginger products — Manage nausea with ginger chews or ginger tea.
-
Water bottle — Stay hydrated to reduce side effects. A large water bottle helps you track intake.
-
Electrolyte packets — Prevent dehydration. Liquid I.V. packets dissolve easily in water.
GLPSpot may earn from qualifying purchases.
CagriSema is a new medication in development from Novo Nordisk — the same company that makes Ozempic. It combines two drugs into one injection. Phase 3 REDEFINE trial results show it produces significantly more weight loss than semaglutide alone.
Quick Comparison
| Ozempic | CagriSema | |
|---|---|---|
| Active drug | Semaglutide | Semaglutide 2.4 mg + Cagrilintide 2.4 mg |
| Drug class | GLP-1 agonist | GLP-1 + Amylin agonist |
| FDA approval | Type 2 diabetes (approved) | In FDA review (decision expected late 2026/early 2027) |
| Dosing | Once weekly | Once weekly |
| Avg weight loss (diabetes) | ~10-12% | 13.7% (REDEFINE 2) |
| Avg weight loss (non-diabetes) | ~10-15% | 20.4% (REDEFINE 1) |
| Status | Available now | Not yet FDA-approved |
What Is CagriSema?
CagriSema combines two drugs:
- Semaglutide — the same drug in Ozempic and Wegovy (GLP-1 agonist)
- Cagrilintide — a new amylin receptor agonist that also signals fullness
Think of it as adding a second fullness signal on top of the GLP-1 signal. Semaglutide reduces appetite and slows stomach emptying through the GLP-1 pathway. Cagrilintide adds a second signal through the amylin pathway — a hormone your body naturally releases after eating to tell your brain you're full.
Weight Loss Results
The Phase 3 REDEFINE program provides detailed trial data:
REDEFINE 1 (People Without Diabetes)
- CagriSema: 20.4% average weight loss over 68 weeks
- Semaglutide 2.4 mg alone: 14.9% average weight loss
- Cagrilintide 2.4 mg alone: 11.5% average weight loss
- Placebo: 3.0%
About 37% of people on CagriSema lost 25% or more of their body weight.
REDEFINE 2 (People With Type 2 Diabetes)
- CagriSema: 13.7% average weight loss over 68 weeks
- Placebo: 3.1%
REDEFINE 2 also showed better blood sugar control than semaglutide alone. HbA1c reductions were greater with the combination. This matters for Ozempic users specifically — many take it for diabetes management, not just weight loss.
What This Means for Ozempic Users
CagriSema offers more weight loss than semaglutide alone — roughly 5-6 percentage points more in non-diabetes patients. For people with type 2 diabetes, the REDEFINE 2 data shows CagriSema provides both better blood sugar control and more weight loss.
How CagriSema Compares to Other Options
| Drug | Avg Weight Loss | Dosing | Status |
|---|---|---|---|
| CagriSema | 20.4% (non-diabetes), 13.7% (diabetes) | Weekly injection | FDA review (decision late 2026/early 2027) |
| Zepbound (tirzepatide) | 15-21% | Weekly injection | FDA approved |
| Wegovy (semaglutide) | ~15% | Weekly injection | FDA approved |
| Ozempic (semaglutide) | ~10-15% | Weekly injection | FDA approved (diabetes) |
| Foundayo (orforglipron) | ~11% | Daily pill | FDA approved (Apr 2026) |
CagriSema's 20.4% weight loss puts it alongside Zepbound at its highest dose. CagriSema uses a different mechanism (GLP-1 + amylin) compared to Zepbound (GLP-1 + GIP). For some people, one approach may work better than the other, but we won't know until there are head-to-head trials.
Why This Matters for Ozempic Users
CagriSema could be the next step for people who:
- Tried semaglutide and didn't lose enough weight
- Want a single injection instead of multiple medications
- Are looking for results closer to what tirzepatide (Mounjaro/Zepbound) offers
- Have type 2 diabetes and want better blood sugar control plus more weight loss
- Prefer to stay with Novo Nordisk products
Side Effects
Based on trial data, CagriSema causes similar side effects to other GLP-1 medications:
- Nausea
- Decreased appetite
- Vomiting
- Diarrhea or constipation
- Stomach pain
About 10-15% of people discontinued treatment due to side effects in the REDEFINE trials — similar to Ozempic. Because CagriSema hits two pathways, some people may experience stronger side effects, but the overall discontinuation rate was comparable. More real-world data is needed once the drug launches.
Availability and FDA Timeline
CagriSema is not yet FDA-approved. Novo Nordisk submitted its FDA application in late 2025. The FDA review timeline is typically 10-12 months for standard review.
Expected FDA decision: Late 2026 or early 2027. If approved, CagriSema would likely launch as a weight loss medication (similar to Wegovy) and possibly for diabetes (similar to Ozempic). Novo Nordisk has also applied for approval in Europe through the EMA.
Cost
No pricing is available yet. Based on the current market:
- Likely priced at a premium over Ozempic since it's a new combination
- Probably around $1,200/month before insurance
- Novo Nordisk's savings card program will likely apply
- Insurance coverage will take time — expect prior authorization requirements
Who Might Benefit from CagriSema?
- People who plateau on semaglutide alone
- People who want stronger weight loss without switching to tirzepatide
- People with type 2 diabetes who want better blood sugar control plus more weight loss
- People who prefer to stay with Novo Nordisk products
It may NOT be worth switching if:
- You're already happy with your current results on Ozempic
- You're doing well on Mounjaro (which has similar weight loss numbers)
- Cost is a major concern (it will likely be expensive at launch)
Bottom Line
CagriSema combines semaglutide with cagrilintide to produce stronger weight loss than semaglutide alone. The REDEFINE 1 trial showed 20.4% weight loss and REDEFINE 2 showed 13.7% weight loss in people with type 2 diabetes. The FDA decision is expected in late 2026 or early 2027.
If you're on Ozempic now and it's working, there's no reason to wait. If you're not getting the results you want, talk to your doctor about your options — including switching to tirzepatide (Mounjaro/Zepbound) while CagriSema is still in FDA review.
Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary. Last updated: June 3, 2026.
